BIOMARKER:

FGFR3 overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

›

FGFR3 overexpression	Urothelial Cancer	FGFR3 overexpression	Urothelial Cancer	atezolizumab + BAY 1163877 Sensitive: C2 – Inclusion Criteria atezolizumab + BAY 1163877 Sensitive : C2	atezolizumab + BAY 1163877 Sensitive: C2 – Inclusion Criteria atezolizumab + BAY 1163877 Sensitive : C2
FGFR3 overexpression	Head and Neck Cancer	FGFR3 overexpression	Head and Neck Cancer	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3	BAY 1163877 Sensitive: C3 – Early Trials BAY 1163877 Sensitive : C3
FGFR3 overexpression	Lung Non-Small Cell Squamous Cancer	FGFR3 overexpression	Lung Non-Small Cell Squamous Cancer	BAY 1163877 Resistant: C3 – Early Trials BAY 1163877 Resistant : C3	BAY 1163877 Resistant: C3 – Early Trials BAY 1163877 Resistant : C3
FGFR3 overexpression	Bladder Cancer	FGFR3 overexpression	Bladder Cancer	TAS 120 Sensitive: D – Preclinical TAS 120 Sensitive : D	TAS 120 Sensitive: D – Preclinical TAS 120 Sensitive : D
FGFR3 overexpression	Squamous Cell Carcinoma of Head and Neck	FGFR3 overexpression	Squamous Cell Carcinoma of Head and Neck	BAY 1163877 Sensitive: D – Preclinical BAY 1163877 Sensitive : D	BAY 1163877 Sensitive: D – Preclinical BAY 1163877 Sensitive : D
FGFR3 overexpression	Squamous Cell Carcinoma of Head and Neck	FGFR3 overexpression	Squamous Cell Carcinoma of Head and Neck	infigratinib Sensitive: D – Preclinical infigratinib Sensitive : D	infigratinib Sensitive: D – Preclinical infigratinib Sensitive : D
FGFR3 overexpression	Breast Cancer	FGFR3 overexpression	Breast Cancer	FGFR inhibitor Sensitive: D – Preclinical FGFR inhibitor Sensitive : D	FGFR inhibitor Sensitive: D – Preclinical FGFR inhibitor Sensitive : D